TrialRheumatology (Oxford, England)2016

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab.

Nathan Vastesaeger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.